Gene silencing and gene editing

Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test

Glow-in-the-dark proteins, developed from the luciferase found in bioluminescent creatures, may make viral disease diagnosis quicker and easier, according to the researchers.

March 15, 2023

Sherlock Biosciences nabs additional patent rights to Cas12 enzyme for CRISPR diagnostics

Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, as well as to additional intellectual property for Cas12 and Cas13 obtained from the Broad Institute.

February 21, 2023

Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption

The acquisition enables Sherlock to combine its CRISPR, synthetic biology, and artificial intelligence technologies with Sense's instrument-free diagnostic hardware and rapid molecular amplification chemistries.

February 1, 2023

AI tool makes speedy gene-editing possible, offers alternative to CRISPR

An artificial intelligence program may enable the first simple production of customizable proteins called zinc fingers to treat diseases by turning genes on and off.

January 26, 2023

Discovery of destructive CRISPR enzyme opens up diagnostic, therapeutic applications for molecular scissors

In a pair of Nature papers, researchers describe the structure and function of Cas12a2, which binds and cuts target DNA to shut off a specific gene so that the enzymes can be used as molecular scissors.

January 4, 2023

Sherlock Biosciences licenses Wyss Institute nucleic acid amplification technology

Sherlock Biosciences will integrate the method with its CRISPR-based Sherlock platform. The aim is to develop diagnostic assays that can detect pathogen- or disease-related nucleic acids at the point-of-need without instruments.

October 17, 2022

Allelica launches polygenic risk score analysis as LDT

The firm said its tests are made possible through a partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, MA.

September 20, 2022

Nucleai, Propath partner on immuno-oncology panel

Propath will develop a novel protocol using the Lunaphore Comet platform for analysis of 30 high-value protein targets from a single tissue section. The platform enables rapid development of highly multiplexed panels, with robust and reproducible staining, Nucleai said.

September 20, 2022

‘Father of microarray technology’ convicted in $77M fraud scheme

Mark Schena participated in a scheme to mislead investors, commit healthcare fraud, and pay illegal kickbacks in connection with the submission of more than $77 million in false and fraudulent claims for such testing, the U.S. Department of Veterans Affairs (VA), Office of Inspector General (OIG), announced Thursday.

September 8, 2022

Thermo Fisher promotes new mass spectrometry instrument

The instrument is called Orbitrap Ascend Tribrid, and it offers capability for multiplexed proteomics and native protein characterization, according to Thermo Fisher. It can analyze more samples at lower concentrations, and features an ion source for calibration the company calls Auto-Ready.

August 28, 2022

Quotient Q1 2023 revenues drop on customer order change

For the quarter ended June 30, the Eysins, Switzerland-based firm posted a net loss of $38.9 million, or $.37 per share, compared to $27.3 million, or $.27 per share, in fiscal Q1 2022.

August 8, 2022

Qiagen expands PCR portfolio, launches custom assay service

New solutions are available with 10 new QIAcuity Cell and Gene Therapy dPCR Assays for use in adeno-associated virus (AAV) titer quantifications. Custom assay design provides users with access to multiplex assays for use beyond biopharma purposes.

July 26, 2022

Page 1 of 5

Next Page